Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 55Neoplasm Metastasis 17Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasms 14Pancreatic Neoplasms 11Uveal Melanoma 10Prostatic Neoplasms 10Leukemia, Myeloid, Acute 9Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Myelodysplastic Syndromes 7Lymphoma 7Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Recurrence 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Glioblastoma 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4

Interventions

Photochemotherapy 41-phenyl-3,3-dimethyltriazene 4sonidegib 2pembrolizumab 2HhAntag691 2Biopsy 2tozuleristide 1tocilizumab 1talimogene laherparepvec 1silmitasertib 1prednylidene 1poly ICLC 1flt3 ligand protein 1deltacortene 1cemiplimab 1Tacrolimus 1TAK-441 1Sirolimus 1SUB1 protein, human 1Radiotherapy 1Radiation 1Prednisone 1Nivolumab 1NVP-LEQ506 1Microarray Analysis 1Mass Spectrometry 1Laser Therapy 1Ipilimumab 1Imiquimod 1Glatiramer Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Basal Cell × Ipilimumab × Clear all
NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡